Expansion at Vertex Pharmaceuticals

| August 6, 2019

article image
Kristy Grimm talks about the expansion of the Medical Affairs team at Vertex.

Spotlight

MIPHARM SPA

Mipharm S.p.A. was born in January 1998 following the merger of Sandoz and Ciba Geigy, from which resulted the new company Novartis. Mipharm was founded by a group of ex managers coming from Novartis by mean of a spin-off of the manufacturing site located in Milan, Via Quaranta, previously owned by Sandoz. In December 2016, Mandarin Capital Partners II acquired the majority stake in Mipharm share capital. Today, Mipharm is one of the most valuable third-party manufacturing and new product development sites in Italy and it claims to have four FDA approvals (Nasal Spray Solution, Oral Potent Drug, Sachet, Packaging).

OTHER ARTICLES

Pricing of drugs – at what cost?

Article | February 27, 2020

We go into a doctor’s office and leave with a diagnosis and a prescription. Next we stop by the pharmacy. In Germany, if your insurance is not private, you mostly don’t even know the price of your drug because it’s paid for directly by your insurance. You only notice the 5-10 Euros copay. But how is a drug priced in Germany? And (how) does data play a role in helping pharma secure an attractive price point? Let’s fast forward directly to the launch of a new drug. At the time of launch, the pharmaceutical company has to present patient level evidence of the drug’s added value compared to existing comparative therapies. In the first year, however, the drug’s price can be defined freely by the company.

Read More
PHARMACY MARKET

A pharma outsourcing mission

Article | February 27, 2020

In a way, getting through the initial stages of a complex pharmaceutical project that is being outsourced to a contract development and manufacturing organization is like getting a rocket off the ground. Many drug developers express frustration with the time it often takes during the initial stages of working with a CDMO — from the time they first reach out to a CDMO for help until they receive a proposal. Some have described it as months of silence from when they send a request for proposal (RFP) until they have a proposal in hand. The initial stages of a relationship between drug sponsor and CDMO often do not get the attention it deserves, and valuable time is lost, delaying projects and delaying delivery of therapeutics to patients. The quick scheduling of the ACT meeting with the right attendees can deliver immediate answers to key questions needed by the drug sponsor for effective planning and can help propel projects to a successful launch.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | February 27, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | February 27, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

Spotlight

MIPHARM SPA

Mipharm S.p.A. was born in January 1998 following the merger of Sandoz and Ciba Geigy, from which resulted the new company Novartis. Mipharm was founded by a group of ex managers coming from Novartis by mean of a spin-off of the manufacturing site located in Milan, Via Quaranta, previously owned by Sandoz. In December 2016, Mandarin Capital Partners II acquired the majority stake in Mipharm share capital. Today, Mipharm is one of the most valuable third-party manufacturing and new product development sites in Italy and it claims to have four FDA approvals (Nasal Spray Solution, Oral Potent Drug, Sachet, Packaging).

Events